ShareValue scores for 002900.SHE: Valuation 52, Quality 19, Growth 38, Health 42.

002900.SHE
SZSE

Harbin Medisan Pharmaceutical Co Ltd

CN¥13.48(+10.04%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

4% to 17%
Valuation
52
Fair Value
Price vs Value
Quality
19
Weak
Business Strength
Growth
38
Weak
Revenue & Earnings
Health
42
Moderate
Financial Stability
Momentum
21
Bearish
Price Trend

Company Details

About

Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium folinate for injection, hydroxylcamptothecine injection, tropisetron hydrochloride for injection, tropisetron hydrochloride and glucose injection, gabexate mesylate for injection, bismuth potassium citrate granules, pantoprazole sodium for injection, ambroxol hydrochloride and glucose injection, asarone for injection, paracetamol and tramadol hydrochloride tablets, rifamycin sodium for injection, lornoxicam for injection, vecuronium bromide for injection, and vitamin c for injection. It also provides medical devices and cosmetics. Harbin Medisan Pharmaceutical Co., Ltd. was founded in 1996 and is headquartered in Harbin, China.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026